In April 2013, the American College of Medical Genetics (ACMG) recommended that clinical
laboratories conducting whole genome sequencing (WGS) and whole exome sequencing (WES) for specific
clinical indications should also analyze and report any mutations identified from a list of 57 genes
considered medically actionable, regardless of whether patients wish to receive the results.1 These recommendations have sparked a heated debate with profound
implications for countless physicians and their patients.
Klitzman R, Appelbaum PS, Chung W. Return of Secondary Genomic Findings vs Patient AutonomyImplications for Medical Care. JAMA. 2013;310(4):369–370. doi:10.1001/jama.2013.41709